Omadacycline Noninferior to Linezolid in ABSSSI Patients With High BMI, Diabetes
Gastrointestinal treatment-emergent adverse events were infrequent across both omadacycline and linezolid treatment. Photo Credit: Dr P Marazzi/Science Source.
|This article is part of Infectious Disease Advisor's in-depth coverage of IDWeek 2017™, which took place in San Diego, CA. Our staff will be reporting on the latest treatment advancements and research initiatives for skin infections. Check back regularly for highlights from IDWeek 2017.|
|Visit Infectious Disease Advisor's conference section for in-depth coverage from IDWeek 2017.|
Wilcox M, Cure-Bolt N, Chitra S, Tzanis E, McGovern P. Efficacy and safety of omadacycline in patients with acute bacterial skin and skin structure infections (ABSSSI) and high body mass index or type 2 diabetes: a subgroup analysis from the OASIS trial. Presented at: IDWeek 2017; October 4-8, 2017; San Diego, CA. Poster 1838.